Groowe Groowe / Newsroom / IVVD
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

IVVD News

Invivyd, Inc. Common Stock

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026

globenewswire.com
IVVD

Adimab Records Another Year of Double-Digit Clinical Program Growth

prnewswire.com
GSK BIIB NVS BMY REGN VRTX LLY MRK ALNY IVVD ALE SCHR

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights

globenewswire.com
IVVD

Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

globenewswire.com
IVVD

Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

globenewswire.com
IVVD

Invivyd to Participate at the 8th Annual Evercore Healthcare Conference

globenewswire.com
IVVD

Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness

globenewswire.com
IVVD

Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants

globenewswire.com
IVVD

Invivyd Announces Proposed Public Offering of Common Stock

globenewswire.com
IVVD

Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights

globenewswire.com
IVVD